MindChild Medical Inc. and the University of Oxford Announce a Sponsored Research Agreement for the Development of Innovative Signal Processing Software for Fetal and Maternal Monitor With the MERIDIAN Non-Invasive Fetal Heart Rate Monitor1
11/5/2012 10:07:20 AM
NORTH ANDOVER, Mass.--(BUSINESS WIRE)--MindChild Medical, Inc., and The University of Oxford today announced the signing of a Sponsored Research Agreement for the development of innovative signal processing algorithms for use with the MERIDIAN™ non-invasive fetal heart monitor. MindChild previously announced clearance for its Pre-Marketing Notification (510(k)) from the US Food and Drug Administration (FDA) for the MERIDIAN™ non-invasive fetal heart monitor. MindChild anticipates entering the US market with MERIDIAN now that it has received the FDA clearance. Additional pre-market regulatory filings are anticipated during 2013.